208 related articles for article (PubMed ID: 11319230)
1. Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Chang JW; Mechling DE; Bächinger HP; Burrows GG
J Biol Chem; 2001 Jun; 276(26):24170-6. PubMed ID: 11319230
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
Li Y; Li H; Martin R; Mariuzza RA
J Mol Biol; 2000 Nov; 304(2):177-88. PubMed ID: 11080454
[TBL] [Abstract][Full Text] [Related]
3. Design, engineering and production of functional single-chain T cell receptor ligands.
Burrows GG; Chang JW; Bächinger HP; Bourdette DN; Offner H; Vandenbark AA
Protein Eng; 1999 Sep; 12(9):771-8. PubMed ID: 10506287
[TBL] [Abstract][Full Text] [Related]
4. Functionally active recombinant alpha and beta chain-peptide complexes of human major histocompatibility class II molecules.
Nag B; Arimilli S; Mukku PV; Astafieva I
J Biol Chem; 1996 Apr; 271(17):10413-8. PubMed ID: 8626615
[TBL] [Abstract][Full Text] [Related]
5. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells.
Vergelli M; Kalbus M; Rojo SC; Hemmer B; Kalbacher H; Tranquill L; Beck H; McFarland HF; De Mars R; Long EO; Martin R
J Neuroimmunol; 1997 Aug; 77(2):195-203. PubMed ID: 9258250
[TBL] [Abstract][Full Text] [Related]
6. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex.
Krogsgaard M; Wucherpfennig KW; Cannella B; Hansen BE; Svejgaard A; Pyrdol J; Ditzel H; Raine C; Engberg J; Fugger L
J Exp Med; 2000 Apr; 191(8):1395-412. PubMed ID: 10770805
[TBL] [Abstract][Full Text] [Related]
7. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein.
Gauthier L; Smith KJ; Pyrdol J; Kalandadze A; Strominger JL; Wiley DC; Wucherpfennig KW
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11828-33. PubMed ID: 9751750
[TBL] [Abstract][Full Text] [Related]
8. Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant alpha and beta polypeptide chains.
Arimilli S; Cardoso C; Mukku P; Baichwal V; Nag B
J Biol Chem; 1995 Jan; 270(2):971-7. PubMed ID: 7529765
[TBL] [Abstract][Full Text] [Related]
9. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones.
Wucherpfennig KW; Sette A; Southwood S; Oseroff C; Matsui M; Strominger JL; Hafler DA
J Exp Med; 1994 Jan; 179(1):279-90. PubMed ID: 7505801
[TBL] [Abstract][Full Text] [Related]
10. Analysis of antibody markers, DRB1, DRB5, DQA1 and DQB1 genes and modeling of DR2 molecules in DR2-positive patients with insulin-dependent diabetes mellitus.
Sanjeevi CB; Lybrand TP; Landin-Olsson M; Kockum I; Dahlquist G; Hagopian WA; Palmer JP; Lernmark A
Tissue Antigens; 1994 Aug; 44(2):110-9. PubMed ID: 7817375
[TBL] [Abstract][Full Text] [Related]
11. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L
Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182
[TBL] [Abstract][Full Text] [Related]
12. Expression of recombinant HLA-DR2 molecules. Replacement of the hydrophobic transmembrane region by a leucine zipper dimerization motif allows the assembly and secretion of soluble DR alpha beta heterodimers.
Kalandadze A; Galleno M; Foncerrada L; Strominger JL; Wucherpfennig KW
J Biol Chem; 1996 Aug; 271(33):20156-62. PubMed ID: 8702739
[TBL] [Abstract][Full Text] [Related]
13. pH dependent binding of high and low affinity myelin basic protein peptides to purified HLA-DR2.
Mukku PV; Passmore D; Phan D; Nag B
Mol Immunol; 1995 Jun; 32(8):555-64. PubMed ID: 7541890
[TBL] [Abstract][Full Text] [Related]
14. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides.
Vogt AB; Kropshofer H; Kalbacher H; Kalbus M; Rammensee HG; Coligan JE; Martin R
J Immunol; 1994 Aug; 153(4):1665-73. PubMed ID: 7519208
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein.
Smith KJ; Pyrdol J; Gauthier L; Wiley DC; Wucherpfennig KW
J Exp Med; 1998 Oct; 188(8):1511-20. PubMed ID: 9782128
[TBL] [Abstract][Full Text] [Related]
16. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes.
Wucherpfennig KW; Hafler DA; Strominger JL
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8896-900. PubMed ID: 7568039
[TBL] [Abstract][Full Text] [Related]
17. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation.
Wang C; Mooney JL; Meza-Romero R; Chou YK; Huan J; Vandenbark AA; Offner H; Burrows GG
J Immunol; 2003 Aug; 171(4):1934-40. PubMed ID: 12902496
[TBL] [Abstract][Full Text] [Related]
18. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice.
Vandenbark AA; Rich C; Mooney J; Zamora A; Wang C; Huan J; Fugger L; Offner H; Jones R; Burrows GG
J Immunol; 2003 Jul; 171(1):127-33. PubMed ID: 12816990
[TBL] [Abstract][Full Text] [Related]
19. Anergy induction by dimeric TCR ligands.
Appel H; Seth NP; Gauthier L; Wucherpfennig KW
J Immunol; 2001 Apr; 166(8):5279-85. PubMed ID: 11290814
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific apoptosis in immortalized T cells by soluble MHC class II-peptide complexes.
Arimilli S; Mumm JB; Nag B
Immunol Cell Biol; 1996 Feb; 74(1):96-104. PubMed ID: 8934660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
